Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk

Despite recent advances in the development of tools to predict immunogenicity risk of biotherapeutic molecules, the ability of a protein to elicit the formation of anti-drug antibodies (ADA) remains one of the most common causes for termination of clinical development programs. In this study, we use...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:MAbs
Auteurs principaux: Bivi, Nicoletta, Moore, Terry, Rodgers, George, Denning, Heather, Shockley, Travis, Swearingen, Craig A., Gelfanova, Valentina, Calderon, Boris, Peterson, Daniel A., Hodsdon, Michael E., Siegel, Robert W., Higgs, Richard E., Konrad, Robert J.
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis 2019
Sujets:
Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6601536/
https://ncbi.nlm.nih.gov/pubmed/31099718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2019.1612699
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires